()
 
 

Overview

Response Genetics, Inc. is engaged in the research and development of pharmacogenomic cancer diagnostic tests based on its proprietary and patented technologies. RGI's technologies enable extraction and analysis of genetic information from genes derived from tumor samples stored as formalin-fixed and paraffin embedded specimens. RGI currently generates revenue primarily from the sales of its proprietary analytical pharmacogenomic testing services of clinical trial specimens to the pharmaceutical industry. The company was founded in 1999 and its principal headquarters are located in Los Angeles, California.


Contact Information


Los Angeles, CA

tel: 323-2243900
fax:
http://www.responsegenetics.com

,  



Investor Relations



tel:
fax:




Stock

Exchange: NASDAQ
Industry: Diagnostic Substances
Market Cap: $34.8M




 
The information provided here has been obtained from publicly available sources as well as directly from issuers in some cases. Please see our Disclaimer and Terms of Service for more information.